Cui Xiangmin's Form 4 filing
CG Oncology, Inc.CGON · filed Jan 31, 2024
- Accession no.
- 0001415889-24-002062
- Filed
- Jan 31, 2024, 4:17 PM ET
- Trade date
- Jan 29, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market purchases total $7.60M. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001415889-24-010609 (Apr 9, 2024). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cui XiangminCIK 0001487815 | 10% Owner |
| Decheng Capital Global Life Sciences Fund IV, L.P.CIK 0001834150 | 10% Owner |
| Decheng Capital Management IV (Cayman), LLCCIK 0001843384 | 10% Owner |
| Decheng Capital Global Healthcare Fund (Master), LPCIK 0001949026 | 10% Owner |
| Decheng Capital Global Healthcare GP, LLCCIK 0001949027 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | Common Stock | CConversionAcquired | +3,628,198 | –F1 | – | 4,558,812 | Direct | |
| Jan 29, 2024 | Common Stock | PPurchaseAcquired | +400,000 | $19.00 | +$7,600,000 | 400,000 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
Referenced by the price of 1 transaction in Table I and 3 transactions in Table II.